Alkaline Phosphatase and Hypophosphatasia.
Millán JL, Whyte MP. · 2016
Read Alkaline Phosphatase and Hypophosphatasia. by Millán JL, Whyte MP. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4824800.txt.
Introduction
José Luis Millán and Michael P. Whyte review alkaline phosphatase and the disease hypophosphatasia in Calcified Tissue International in 2016. The enzyme at issue works in bone, liver, and kidney, clearing a compound that blocks mineral from hardening into bone and teeth. Faults in its gene drain its activity, so the blocker piles up and the skeleton stays soft: the rickets-like disease hypophosphatasia.
The review gathers what the enzyme does, how the disease varies from lethal infant forms to adult tooth trouble, and what mouse and patient studies have revealed. A turning point is enzyme replacement: a bone-targeted copy of the enzyme, given from birth, rescued mice and then infants and children with life-threatening disease. Trials since have exposed surprise features of the disease, and new treatments are in development.
Catalog record
| CREATOR | Millán JL, Whyte MP. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Alkaline Phosphatase and Hypophosphatasia By José Luis Millán, Michael P Whyte Published in: Calcified Tissue International DOI: 10.1007/s00223-015-0079-1 ABSTRACT Abstract Hypophosphatasia (HPP) results from ALPL mutations leading to deficient activity of the tissue-non-specific alkaline phosphatase isozyme (TNAP) and thereby extracellular accumulation of inorganic pyrophosphate (PPi), a natural substrate of TNAP and potent inhibitor of mineralization. Thus, HPP features rickets or osteomalacia and hypomineralization of teeth. Enzyme replacement using mineral-targeted TNAP from birth prevented severe HPP in TNAP-knockout mice and was then shown to rescue and substantially treat infants and young children with life-threatening HPP. Clinical trials are revealing aspects of HPP pathophysiology not yet fully understood, such as craniosynostosis and muscle weakness when HPP is severe. New treatment approaches are under development to improve patient care. Keywords: Rickets, Osteomalacia, Enzyme replacement, Calcification, Seizures INTRODUCTION In 1923, Robert Robison, Ph.D. discovered a phosphatase abundant in the skeleton possibly to generate inorganic phosphate (Pi) required to form bone mineral [1]. In 1932, he postulated that an additional but unknown factor regulates skeletal mineralization [2]. This factor would prove to be inorganic pyrophosphate (PPi), a potent inhibitor of mineralization and natural substrate for Robison’s enzyme [3]. The phosphatase, now called tissue-non-specific alkaline phosphatase (TNAP, or TNSALP), is encoded by the ALPL gene [4] expressed richly in bone, liver, and kidney, but also in the central nervous system, fibroblasts, and endothelial and other cell types. Hypomorphic ALPL mutation(s) cause hypophosphatasia (HPP) [4], a rare form of rickets or osteomalacia [5] featuring low serum alkaline phosphatase (ALP) activity and with an incidence for its most severe forms of 1:100,000 [6] and 1:300,000 [7] in the general population [6] of North America and Europe, respectively, but 1 per 2500 births in Canadian Mennonites [8]. The efficacy of enzyme replacement therapy (EzRT) using a mineral-targeted form of recombinant TNAP has been demonstrated for severe HPP [9]. Our review summarizes knowledge concerning TNAP, including revelations about its physiological function coming from investigation of HPP patients and mouse models and successes using EzRT. THE ENZYME In humans, three genes besides ALPL (ALPI, ALPP, and ALPPL2) encode alkaline phosphatase (ALP) isozymes, but with restricted tissue expression; i.e., “intestinal,” “placental,” and “germ cell” ALP and are not compromised in HPP [10]. TNAP structure modeling is based on its sequence homology to the placental isozyme (PLAP) for which crystallographic coordinates have been determined [11]. TNAP functions physiologically as a homodimer (Fig. 1) [12]. The two monomers become related by a twofold crystallographic axis, with the monomer–monomer interface displaying a strong hydrophobic character with fewer than 30 % of its amino acid residues (hereafter “residues”) involved in hydrogen-bonding interactions [13]. This feature renders the monomer–monomer interface crucial for stability and enzymatic function, and TNAP (and mammalian ALPs in general) is therefore an obligatory homodimer. A flexible surface loop, “the crown domain,” contains residues important for stabilizing the binding of uncompetitive TNAP inhibitors, such as E429 and Y367 [14–16]. Furthermore, this domain contains a low-affinity collagen-binding motif [16]. The N-terminal α-helix (residues 9–25) of each monomeric subunit reaches the active site of the contralateral subunit (Fig. 1) [17]. Both the crown domain and the N-terminal arm help stabilize the dimeric structure and determine allosteric properties [18]. Thus, structural and functional properties explain how some hypomorphic ALPL alleles compromise the kinetic properties of the entire dimer (a dominant-negative effect) leading to TNAP insufficiency and generation-to-generation inheritance of HPP [19]. Three metal-binding sites surrounding the catalytic Ser residue are essential for TNAP enzymatic activity; i.e., M1 and M2 (occupied by Zn2+) and M3 (occupied by Mg2+) [11, 14]. An additional metal-binding site, M4, apparently occupied by Ca2+ and absent in bacterial ALPs, was revealed by solving the 3D structure of PLAP [11, 20]. However, this M4 structural metal site does not influence TNAP catalytic activity [21]. During TNAP-mediated catalysis, Zn2+ ions occupy the M1 and M2 sites, Mg2+ the M3 site, and Ca2+ the M4 site. With skeletal mineralization, the increasing Ca2+ gradient in the extracellular matrix first activates TNAP by replacing the Mg2+ with Ca2+ at M3, but at high Ca2+ concentrations, it gradually deactivates TNAP as Ca2+ competes out the Zn2+ from the M1 and M2 metal sites [21]. This explains why TNAP loses activity at the completion of the mineralization process [22]. [Figure: Ribbon representation of the 3D structure of alkaline phosphatase (1EW2) [10]. The active site phosphate (PO4 3−) bound to Ser92 during catalysis is shown in green. The three active site metal ions, two Zn2+ (Zn1 and Zn2) and one Mg2+ (Mg), are shown in white as well as the structural Ca2+ ion (Ca). Also indicated are the flexible exposed sequence known as the “crown domain”; the N-terminal helix of one subunit that reaches close to the active site of the contralateral subunit; and the location where the glycosylphosphatidylinositol (GPI) anchor is attached to the C-terminus of the mature enzyme (Color figure online)] Thus, ALPL mutations that alter residues at the monomer–monomer interface, the crown domain, the N-terminal arm, and the divalent cation-binding sites can all cause HPP [20]. Additionally, post-translational modifications of TNAP are important. TNAP (indeed all mammalian ALPs) is bound to the surface of plasma membranes via a glycosylphosphatidylinositol (GPI) anchor that enables movement of the enzyme by enhancing membrane fluidity [23]. This GPI anchor can be cleaved by the enzymatic action of phospholipases found in plasma membranes, perhaps explaining how TNAP is released into the circulation and other biological fluids [24]. Also, TNAP contains five putative N-linked glycosylation sites, N123, N213, N254, N286, and N413 [25], with the sugar chains required for catalytic activity [26]. The types of sugars in TNAP explain the different biophysical and kinetic properties of its “isoforms” produced by bone, liver, kidney, and vascular cells [27]. In vitro, TNAP has broad substrate specificity and can hydrolyze or transphosphorylate a considerable variety of compounds [10]. However, only a few [inorganic pyrophosphate (PPi), pyridoxal 5′-phosphate (PLP), and likely phosphoethanolamine (PEA)] are natural substrates for TNAP based on studies of HPP patients and fibroblasts and Alpl knockout (KO) mice [28, 29]. Nevertheless, it is unclear what metabolic pathway leads to PEA accumulation [27, 29]. Recent studies also suggest that ATP [30–32], di-phosphoryl lipopolysaccharide (LPS) [33], and phosphorylated osteopontin (p-OPN) [34] are natural substrates of TNAP. THE DISEASE HPP features extraordinarily broad-ranging severity (Fig. 2), but all patients carry one or two loss-of-function mutations in their ALPL alleles [4, 35, 36]. Traditionally, HPP is classified in the clinic firstly by whether there are dental manifestations alone (i.e., without skeletal disease or other complications), and then according to the patient’s age when any additional complications initially manifested. Thus, in order of decreasing severity, clinicians recognize perinatal HPP, infantile HPP, childhood HPP, adult HPP, and odonto-HPP [35]. Perinatal HPP is detectable in utero using fetal sonography, and can cause stillbirth or be fatal soon after [37]. Infantile HPP presents before 6 months-of-age, often with rickets, failure-to-thrive, hypotonia, and muscle weakness, and can be complicated by hypercalcemia, nephrocalcinosis, vitamin B6-dependent seizures, and craniosynostosis [5, 38]. Vitamin B6-dependent seizures and skeletal deterioration predict death from respiratory complications [36]. If there is survival beyond infancy, deciduous teeth are lost prematurely (i.e., before the patient’s 5th birthday) because insufficiently mineralized cementum can not